Local bevacizumab treatment of juvenile-onset respiratory papillomatosis might induce multiple tracheal pyogenic granulomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F21%3AE0108733" target="_blank" >RIV/00843989:_____/21:E0108733 - isvavai.cz</a>

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/lary.28928" target="_blank" >https://onlinelibrary.wiley.com/doi/full/10.1002/lary.28928</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/lary.28928" target="_blank" >10.1002/lary.28928</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Local bevacizumab treatment of juvenile-onset respiratory papillomatosis might induce multiple tracheal pyogenic granulomas

Popis výsledku v původním jazyce

Juvenile-onset recurrent respiratory papillomatosis (JORRP) is the most common pediatric neoplastic disease of the airway. Its estimated annual incidence is 0.17–1.34 per 100,000 children. Although multiple treatment strategies for JORRP exist, surgical debulking remains the therapeutic mainstay. In the last 10 years, the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, has been administered to adults and children with severe disease, and it has shown promising effects. For aggressive laryngeal disease, bevacizumab is administered with an intra-lesion or sub-lesion injection. When tracheobronchial involvement is extensive, intravenous bevacizumab administration might be considered.1, 2 To date, no adverse effect has been reported for local bevacizumab applications. Here, we present the first case of a multiple tracheal pyogenic granuloma that developed after intra-epithelial bevacizumab application in a 2-year-old child.

Název v anglickém jazyce

Local bevacizumab treatment of juvenile-onset respiratory papillomatosis might induce multiple tracheal pyogenic granulomas

Popis výsledku anglicky

Juvenile-onset recurrent respiratory papillomatosis (JORRP) is the most common pediatric neoplastic disease of the airway. Its estimated annual incidence is 0.17–1.34 per 100,000 children. Although multiple treatment strategies for JORRP exist, surgical debulking remains the therapeutic mainstay. In the last 10 years, the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, has been administered to adults and children with severe disease, and it has shown promising effects. For aggressive laryngeal disease, bevacizumab is administered with an intra-lesion or sub-lesion injection. When tracheobronchial involvement is extensive, intravenous bevacizumab administration might be considered.1, 2 To date, no adverse effect has been reported for local bevacizumab applications. Here, we present the first case of a multiple tracheal pyogenic granuloma that developed after intra-epithelial bevacizumab application in a 2-year-old child.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30206 - Otorhinolaryngology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The Laryngoscope

ISSN

0023-852X

e-ISSN

1531-4995

Svazek periodika

131

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

1

Strana od-do

e518-e520

Kód UT WoS článku

000545782900001

EID výsledku v databázi Scopus

2-s2.0-85087657350